Evidence map›Paper›PMID 39835155›Full record

ArticleFrontiers in neurology2024

Applicability of a serodiagnostic line blot for idiopathic inflammatory myopathy: the muscle biopsy is not all.

Pedro Nogueira Fontana, Vinícius Gomes da Silva, Roseli Corazzini, Natália Merten Athayde, Ana Marina Dutra Ferreira da Silva, Igor Brockhausen, Carolina da Cunha Correia, Cláudia Ferreira da Rosa Sobreira, Pedro Tomaselli, Flávio Petean and 8 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Pedro Nogueira FontanaNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Vinícius Gomes da SilvaNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Roseli CorazziniNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Natália Merten AthaydeNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Ana Marina Dutra Ferreira da SilvaNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Igor BrockhausenNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Carolina da Cunha CorreiaFaculty of Medical Sciences, Universidade de Pernambuco, Recife, Brazil.
Cláudia Ferreira da Rosa SobreiraDepartment of Neurosciences and Behavioral Sciences, Universidade de São Paulo - Ribeirão Preto, São Paulo, Brazil.
Pedro TomaselliDepartment of Neurosciences and Behavioral Sciences, Universidade de São Paulo - Ribeirão Preto, São Paulo, Brazil.
Flávio PeteanDepartment of Neurosciences and Behavioral Sciences, Universidade de São Paulo - Ribeirão Preto, São Paulo, Brazil.
Rodrigo de OliveiraDepartment of Neurosciences and Behavioral Sciences, Universidade de São Paulo - Ribeirão Preto, São Paulo, Brazil.
Pablo Vinícius FeitozaDepartment of Clinical Surgery, Faculty of Medicine, Universidade Federal do Amazonas, Manaus, Brazil.
Michel Moraes SoaneEUROIMMUN Brazil, São Caetano do Sul, Brazil.
Natália SaraivaEUROIMMUN Brazil, São Caetano do Sul, Brazil.
Rafaela HidalgoEUROIMMUN Brazil, São Caetano do Sul, Brazil.
Cláudia FidelesEUROIMMUN Brazil, São Caetano do Sul, Brazil.
David FederNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.
Alzira Alves de Siqueira CarvalhoNeurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Differential diagnosis of rare idiopathic inflammatory myopathies (IIM) is mainly based on clinical aspects, muscle biopsy analysis, and auxiliary assays that determine myositis-specific and associated autoantibodies (MSA and MAA). While MSAs are considered specific for their respective IIM subclass, MAAs can be present in more than one subclass and in other conditions. This study compares results of a multispecific line blot assay with the final diagnosis of IIM patients based on clinical features and muscle biopsy to draw conclusions for the test's applicability in the diagnostic workflow. Methods: Samples from patients ( Results: MSA and MAA were detected in 74.0% (37/50) of sera and were concordant with the final diagnosis in 64.8% (24/37), discordant in 16.2% (6/37) and not evaluable in 18.9% (7/37) of cases. In 100% (5/5) of patients with other myopathies, no MSA was found. MSA/MAA-co-positivity was observed in 18.0% (9/50) of patients. In 30.0% (15/50) of cases, the muscle biopsy analysis was essential to establish the final diagnosis. Conclusion: The agreement between serodiagnostic results and final diagnosis highlights the applicability of the EUROIMMUN myositis-related diagnostic test as first line diagnostic tool in the IIM diagnosis workflow and suggests morphological analysis in cases of inconclusive or negative serology. However, results of diagnostic assays shall always be interpreted in combination with clinical features.

Indexed as

anti-synthetase syndromedermatomyositisidiopathic inflammatory myopathiesimmune-mediated necrotizing myopathyinclusion body myositismuscle biopsymyositis-associated antibodiesmyositis-specific antibodies

Identifiers

PMID39835155
PMCPMC11743459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.